BioWorld

July 27, 2009

Rigel Takes Hit on R788 Data, But Partnering Thesis Intact

Rigel Pharmaceuticals Inc. said a midstage study of rheumatoid arthritis drug R788 missed the mark, a development that might complicate partnership talks but won't end them. (BioWorld Today) Read More

VC Money: Biotech Finds a Cure for the Low-Cash Summer Blues

Vertex's Future Milestone Sale Creative If There's a Market

NewCo News: Intellikine Moves into Busy P13K Space with Tricks Up Its Sleeve

CytRx Bolsters Cash by $20M to Boost Lead Drug Programs

Not Satisfied with $80B, Will Obama Get More from PhRMA?

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...